Results 231 to 240 of about 164,625 (307)

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

open access: yesActa Paediatrica, Volume 115, Issue 11, Page 2603-2615, November 2026.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz   +17 more
wiley   +1 more source

Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1275-1284, November 2026.
ABSTRACT Objectives Pediatric acute myeloid leukemia (AML) chemotherapy regimens are frequently burdened by fever episodes, systemic inflammation and bloodstream infections (BSI). Mucosal barrier injury may contribute to these complications, but its role in childhood AML remains uninvestigated.
Carla Warley Kjær   +8 more
wiley   +1 more source

Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics

open access: yesMycoses, Volume 69, Issue 11, November 2026.
ABSTRACT Introduction Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology.
Natalia Mendoza‐Palomar   +14 more
wiley   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy